Seelos Therapeutics Inc
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-004, an gene therap… Read more
Seelos Therapeutics Inc (SEEL) - Net Assets
Latest net assets as of June 2024: $-28.13 Million USD
Based on the latest financial reports, Seelos Therapeutics Inc (SEEL) has net assets worth $-28.13 Million USD as of June 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.38 Million) and total liabilities ($30.51 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-28.13 Million |
| % of Total Assets | -1181.56% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | -1846.22% |
| Growth Volatility | 529.53 |
Seelos Therapeutics Inc - Net Assets Trend (1997–2023)
This chart illustrates how Seelos Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Seelos Therapeutics Inc (1997–2023)
The table below shows the annual net assets of Seelos Therapeutics Inc from 1997 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $-33.51 Million | -215.80% |
| 2022-12-31 | $-10.61 Million | -118.51% |
| 2021-12-31 | $57.32 Million | +2128.73% |
| 2020-12-31 | $2.57 Million | +36842.86% |
| 2019-12-31 | $-7.00K | -100.27% |
| 2018-12-31 | $2.57 Million | -41.16% |
| 2017-12-31 | $4.37 Million | +158.16% |
| 2016-12-31 | $-7.52 Million | +24.42% |
| 2015-12-31 | $-9.94 Million | -618.19% |
| 2014-12-31 | $1.92 Million | -82.51% |
| 2013-12-31 | $10.97 Million | +65.72% |
| 2012-12-31 | $6.62 Million | +37.42% |
| 2011-12-31 | $4.82 Million | -58.34% |
| 2010-12-31 | $11.57 Million | +327.54% |
| 2009-12-31 | $2.71 Million | +76.58% |
| 2008-12-31 | $1.53 Million | -68.11% |
| 2007-12-31 | $4.80 Million | -58.24% |
| 2006-12-31 | $11.50 Million | +779.42% |
| 2005-12-31 | $1.31 Million | -88.53% |
| 2004-12-31 | $11.40 Million | -10.39% |
| 2003-12-31 | $12.72 Million | +294.71% |
| 2002-12-31 | $3.22 Million | -86.63% |
| 2001-12-31 | $24.11 Million | -37.78% |
| 2000-12-31 | $38.74 Million | +461.51% |
| 1999-12-31 | $6.90 Million | +513.31% |
| 1998-12-31 | $-1.67 Million | -80.23% |
| 1997-12-31 | $-926.26K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Seelos Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 24444456600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $10.00K | % |
| Other Components | $219.11 Million | % |
| Total Equity | $-33.51 Million | 100.00% |
Seelos Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Seelos Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CVS GROUP
BE:4C9
|
$144.49K |
|
PT Perma Plasindo Tbk
JK:BINO
|
$144.58K |
|
MINEBEA (MEA.SG)
STU:MEA
|
$144.60K |
|
RACL Geartech Limited
NSE:RACLGEAR
|
$144.64K |
|
SECURITAS -B- (S7MB.SG)
STU:S7MB
|
$144.43K |
|
KYOCERA
MU:KYR
|
$144.36K |
|
SFC ENERGY - Dusseldorf Stock Exchang
DU:F3C
|
$144.35K |
|
Boss Holdings Inc
PINK:BSHI
|
$144.31K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Seelos Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from -10,611,000 to -33,509,999, a change of -22,898,999.
- Net loss of 37,882,000 reduced equity.
- Share repurchases of 1,195,000 reduced equity.
- New share issuances of 20,114,000 increased equity.
- Other factors decreased equity by 3,935,999.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-37.88 Million | -113.05% |
| Share Repurchases | $1.20 Million | -3.57% |
| Share Issuances | $20.11 Million | +60.02% |
| Other Changes | $-3.94 Million | -11.75% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Seelos Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1997-12-31 | $-686.12 | $0.39 | x |
| 1998-12-31 | $-1440.89 | $0.39 | x |
| 1999-12-31 | $2263.04 | $0.39 | x |
| 2000-12-31 | $7973.69 | $0.39 | x |
| 2001-12-31 | $4257.08 | $0.39 | x |
| 2002-12-31 | $538.51 | $0.39 | x |
| 2003-12-31 | $1701.67 | $0.39 | x |
| 2004-12-31 | $1176.72 | $0.39 | x |
| 2005-12-31 | $112.08 | $0.39 | x |
| 2006-12-31 | $782.72 | $0.39 | x |
| 2007-12-31 | $263.64 | $0.39 | x |
| 2008-12-31 | $82.39 | $0.39 | x |
| 2009-12-31 | $137.42 | $0.39 | x |
| 2010-12-31 | $292.90 | $0.39 | x |
| 2011-12-31 | $72.19 | $0.39 | x |
| 2012-12-31 | $72.34 | $0.39 | x |
| 2013-12-31 | $95.65 | $0.39 | x |
| 2014-12-31 | $14.53 | $0.39 | x |
| 2015-12-31 | $-1799.82 | $0.39 | x |
| 2016-12-31 | $-68.16 | $0.39 | x |
| 2017-12-31 | $331.14 | $0.39 | x |
| 2018-12-31 | $25.04 | $0.39 | x |
| 2019-12-31 | $-0.01 | $0.39 | x |
| 2020-12-31 | $1.72 | $0.39 | x |
| 2021-12-31 | $18.92 | $0.39 | x |
| 2022-12-31 | $-2.99 | $0.39 | x |
| 2023-12-31 | $-6.84 | $0.39 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Seelos Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1719.56%
- • Asset Turnover: 0.41x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-290.42%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1997 | 0.00% | -6866.87% | 0.02x | 0.00x | $-3.76 Million |
| 1998 | 0.00% | -83.71% | 0.96x | 0.00x | $-4.54 Million |
| 1999 | -36.23% | -166.67% | 0.20x | 1.10x | $-3.19 Million |
| 2000 | -22.79% | -883007100.00% | 0.00x | 1.03x | $-12.70 Million |
| 2001 | -67.09% | -23755.47% | 0.00x | 1.13x | $-18.59 Million |
| 2002 | -857.50% | -18673.17% | 0.01x | 4.39x | $-27.96 Million |
| 2003 | -135.45% | -15562.03% | 0.00x | 1.82x | $-18.51 Million |
| 2004 | -149.31% | -4737.09% | 0.02x | 1.78x | $-18.16 Million |
| 2005 | -1180.45% | -643.66% | 0.18x | 10.19x | $-15.57 Million |
| 2006 | -69.91% | -430.83% | 0.09x | 1.73x | $-9.19 Million |
| 2007 | -182.89% | -691.71% | 0.12x | 2.22x | $-9.27 Million |
| 2008 | -337.52% | -86.80% | 0.70x | 5.59x | $-5.32 Million |
| 2009 | -1184.39% | -1077.53% | 0.14x | 7.74x | $-32.31 Million |
| 2010 | -255.11% | -593.40% | 0.26x | 1.63x | $-30.67 Million |
| 2011 | -376.02% | -441.76% | 0.25x | 3.45x | $-18.60 Million |
| 2012 | -479.85% | -377.51% | 0.35x | 3.61x | $-32.43 Million |
| 2013 | -154.37% | -674.55% | 0.11x | 2.12x | $-18.04 Million |
| 2014 | -1135.28% | -235.30% | 0.63x | 7.72x | $-21.98 Million |
| 2015 | 0.00% | -393.12% | 0.62x | 0.00x | $-18.03 Million |
| 2016 | 0.00% | -128.98% | 1.23x | 0.00x | $-6.68 Million |
| 2017 | 7.34% | 0.00% | 0.00x | 1.53x | $-116.10K |
| 2018 | -359.33% | 0.00% | 0.00x | 1.46x | $-9.50 Million |
| 2019 | 0.00% | -13435.47% | 0.03x | 0.00x | $-50.38 Million |
| 2020 | -747.28% | -5125.33% | 0.02x | 6.80x | $-19.48 Million |
| 2021 | -117.81% | 0.00% | 0.00x | 1.46x | $-73.27 Million |
| 2022 | 0.00% | -9423.02% | 0.04x | 0.00x | $-75.08 Million |
| 2023 | 0.00% | -1719.56% | 0.41x | 0.00x | $-34.53 Million |
Industry Comparison
This section compares Seelos Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Seelos Therapeutics Inc (SEEL) | $-28.13 Million | 0.00% | N/A | $144.49K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |